Biohit OyjLTS:0DRP 79 Days Payable is 77.60 as of Dec. 2025, which is 23% above its 10-year median of 62.97. GuruFocus rates LTS:0DRP with a GF Score™ of 79/100 and a GF Value™ of €2.70 (Fairly Valued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 50.94% on this metric.
Biohit Oyj's average Accounts Payable for the
six
months ended in Dec. 2025 was €1.02 Mil. Biohit Oyj's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €2.40 Mil.
Hence, Biohit Oyj's Days Payable for the
six
months ended in Dec. 2025 was 77.60.
The historical rank and industry rank for Biohit Oyj's Days Payable or its related term are showing as below:
LTS:0DRP'
s Days Payable Range Over the Past 10 Years
Min: 42.23 Med: 62.97 Max: 85.4
Current: 67.54
During the past 13 years, Biohit Oyj's highest Days Payable was 85.40. The lowest was 42.23. And the median was 62.97.
LTS:0DRP's Days Payable is ranked worse than 50.94% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs LTS:0DRP: 67.54
Biohit Oyj's Days Payable
increased
from Dec. 2024 (61.34) to Dec. 2025 (77.60).
It may suggest that Biohit Oyjdelayed paying its suppliers.
Biohit Oyj Days Payable Related Terms
Biohit Oyj Days Payable Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Biohit Oyj's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Days Payable distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biohit Oyj's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Days Payable of 77.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biohit Oyj and its competitors. This is 23% above median its historical median of 62.97. Over the past decade, Biohit Oyj's Days Payable has ranged from 42.23 to 85.40. According to the industry distribution chart, Biohit Oyj ranks #405 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 50.9%.
Is Biohit Oyj's Days Payable too high?
Biohit Oyj's current Days Payable of 77.60 is 23% above median its 10-year median of 62.97. Over the past 10 years, this metric has ranged from a low of 42.23 to a high of 85.40. The Medical Devices & Instruments industry median Days Payable is 68.07. Biohit Oyj's value of 77.60 is 14% above this industry median. Based on the distribution chart, Biohit Oyj ranks #405 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #405 out of 795 companies for Days Payable. This places Biohit Oyj in the lower half of its industry. The industry median Days Payable is 68.07. Biohit Oyj's value of 77.60 is 14% above this benchmark. Historically, Biohit Oyj's own Days Payable has ranged from 42.23 to 85.40 over the past decade. While the company's 10-year median is 62.97 vs. the industry median of 68.07, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current Days Payable of 77.60 is 14% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Days Payable is 77.60, which is 23% above median its own 10-year median of 62.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.62 — trading 3% below its estimated fair value. The current Days Payable is 77.60, which is 23% above median its 10-year median of 62.97 and 14% above the Medical Devices & Instruments industry median of 68.07. Biohit Oyj's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Days Payable is 77.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.62 is trading 3% below its estimated GF Value™ of €2.70.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Days Payable: 77.60 (23% above median its 10-year median of 62.97)
GF Value™: €2.70 vs. price of €2.62 (3% below fair value)
Industry Position: 14% above the Medical Devices & Instruments median (#405 of 795)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
79GF Score
Get the complete analysis for LTS:0DRP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
